Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes-Reference-Cited by-同舟云学术

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes

Published:2020-12 Issue: Volume:22 Page:34-44
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Ben-Salem Salma^ORCID,Hu Qiang,Liu Yang,Alshalalfa Mohammed,Zhao Xin,Wang Irene,Venkadakrishnan Varadha Balaji^ORCID,Senapati Dhirodatta,Kumari Sangeeta,Liu Deli,Sboner Andrea,Barbieri Christopher E.,Feng Felix,Billaud Jean-Noel,Davicioni Elai,Liu Song,Heemers Hannelore V.

Funder

NIH

NCI

Publisher

Elsevier BV

Subject

Urology

Reference32 articles.

1. NCCN clinical practice guidelines in oncology (NCCN guidelines). Prostate cancer version 2.2019;NCCN,2019

2. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019

3. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase;Cancer Research;2023-10-06

2. Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications;Endocrine-Related Cancer;2023-06-06

3. Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus;International Journal of Radiation Oncology*Biology*Physics;2022-12

4. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity;Frontiers in Endocrinology;2022-07-14

5. PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?;European Urology Focus;2022-07